相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani
Arpita Kulshrestha et al.
PARASITOLOGY RESEARCH (2013)
Characterization and identification of suspected counterfeit miltefosine capsules
Thomas P. C. Dorlo et al.
ANALYST (2012)
Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis
Thomas P. C. Dorlo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use
Shyam Sundar et al.
CLINICAL INFECTIOUS DISEASES (2012)
Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex
Tim Downing et al.
INFECTION GENETICS AND EVOLUTION (2012)
Leishmaniasis Worldwide and Global Estimates of Its Incidence
Jorge Alvar et al.
PLOS ONE (2012)
Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis
Vasundhra Bhandari et al.
PLOS NEGLECTED TROPICAL DISEASES (2012)
Immunity to Visceral Leishmaniasis Using Genetically Defined Live-Attenuated Parasites
Angamuthu Selvapandiyan et al.
JOURNAL OF TROPICAL MEDICINE (2012)
Leishmania Resistance to Miltefosine Associated with Genetic Marker
Sandrine Cojean et al.
EMERGING INFECTIOUS DISEASES (2012)
Phase IV Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala-Azar) in Bangladesh
Mahmudur Rahman et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance
Tim Downing et al.
GENOME RESEARCH (2011)
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial
Shyam Sundar et al.
LANCET (2011)
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Shyam Sundar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal
S. Rijal et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2010)
In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences
Marieke Vermeersch et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent
Mohammad Zahangir Alam et al.
INFECTION GENETICS AND EVOLUTION (2009)
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients
Thomas P. C. Dorlo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru
Alejandro Llanos-Cuentas et al.
CLINICAL INFECTIOUS DISEASES (2008)
Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry
Thomas P. C. Dorlo et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
World antimalarial resistance network I: Clinical efficacy of antimalarial drugs
Ric N. Price et al.
MALARIA JOURNAL (2007)
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo
Karin Seifert et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Mechanisms of experimental resistance of Leishmania to miltefosine:: Implications for clinical use
F. Javier Perez-Victoria et al.
DRUG RESISTANCE UPDATES (2006)
Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug
FJ Pérez-Victoria et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline
S Rijal et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2003)
Oral miltefosine for Indian visceral leishmaniasis
S Sundar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
A policy for leishmaniasis with respect to the prevention and control of drug resistance
A Bryceson
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2001)
分享论文
